Double-Drug attack: new combo aims to tackle tough lung cancer
NCT ID NCT07714304
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment for advanced disease will receive the combination. The study first checks for safety in a small group, then expands to see how well the drugs work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental drug called JS212 (given by IV infusion) and another drug called JS111 (taken as a capsule)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a common type of advanced lung cancer.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes over existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230088, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.